Your browser doesn't support javascript.
loading
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.
Dagenais, Gilles R; Dyal, Leanne; Bosch, Jacqueline J; Leong, Darryl P; Aboyans, Victor; Berkowitz, Scott D; Bhatt, Deepak L; Connolly, Stuart J; Fox, Keith A A; Muehlhofer, Eva; Probstfield, Jeffrey L; Widimsky, Petr; Winkelmann, Bernhard R; Yusuf, Salim; Eikelboom, John W.
Affiliation
  • Dagenais GR; Department of Cardiology, Laval University Heart and Lung Institute, Quebec, Québec, Canada gilles.dagenais@criucpq.ulaval.ca.
  • Dyal L; Population Health Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, Ontario, Canada.
  • Bosch JJ; Population Health Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, Ontario, Canada.
  • Leong DP; Population Health Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, Ontario, Canada.
  • Aboyans V; Department of Cardiology, Dupuytren University Hospital, Limoges, France.
  • Berkowitz SD; Department of Cardiology, INSERM, U1094, Tropical Neuroepidemiology, Limoges, France.
  • Bhatt DL; Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA.
  • Connolly SJ; Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts, USA.
  • Fox KAA; Population Health Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, Ontario, Canada.
  • Muehlhofer E; Department of Medicine, University of Edinburgh, Edinburgh, UK.
  • Probstfield JL; Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA.
  • Widimsky P; Department of Medicine (Cardiology), University of Washington Medical Centre, Seattle, Washington, USA.
  • Winkelmann BR; Cardiocenter, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University Prague, Prague, Czech Republic.
  • Yusuf S; Kardiologische Studienpraxis und ClinPhenomics GmbH&Co, Studienzentrum Schaumainkai Frankfurt, Frankfurt, Germany.
  • Eikelboom JW; Population Health Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, Ontario, Canada.
Heart ; 107(14): 1130-1137, 2021 07.
Article in En | MEDLINE | ID: mdl-34021038
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Aspirin / Coronary Disease / Withholding Treatment / Peripheral Arterial Disease / Rivaroxaban / Ischemic Stroke / Myocardial Infarction Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies Limits: Aged / Female / Humans / Male Language: En Journal: Heart Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Aspirin / Coronary Disease / Withholding Treatment / Peripheral Arterial Disease / Rivaroxaban / Ischemic Stroke / Myocardial Infarction Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies Limits: Aged / Female / Humans / Male Language: En Journal: Heart Year: 2021 Document type: Article